- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05885828
De PRECISION-T2D-studie: precisievoedingsstudie voor diabetes type 2
Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.
In this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
Choice of design: The study is a two-arm intervention study integrated with N-of-1 design.
Study population: Patients with type 2 diabetes.
Screening Assessment: Prospective participants will be selected based on the pre-defined inclusion and exclusion criteria. Recruitment will be done over the phone and via the social media.
Study duration: Each participant will take part in the study for a period of up to 1 month at baseline and have follow-up visits every 1-2 years.
Dietary intervention:
The PRECISION-T2D is a dietary intervention study. Upon admission, patients will be randomly assigned to two groups: plant-based diet and conventional diabetic diet. Throughout the hospitalization, all participants (n=200) will be given standardized meals. A dietitian will design the diet for both plant-based and conventional diabetic diet groups following 2023 Chinese Diabetes Society guidelines. Both diets comprised approximately 50-65% of energy from carbohydrates, 20-30% of energy from fat, 15-20% from protein. The plant-based diet had higher fiber content (25-30g) compared to the conventional diabetic diet (15-20g). Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any leftover food. All participants will be asked to track their meals, snacks and drinks with instructions on how to record their daily dietary information. Participants will also be advised not to modify their exercise habits during the course of the study. Upon discharge, Participants in the plant-based diet arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. Participants in the conventional diabetic diet arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. Individual N-of-1 trial design will be employed to all participants during day one to day twelve to compare the difference of postprandial glucose response to white bread or whole wheat bread. These two standard breakfasts will appear in pseudo-random order. During the participants' first baseline visit day, they will be asked to complete a baseline questionnaire to collect information on their lifestyle, dietary habits, history of medications, sleep quality and appetite. Anthropometric measurements, ultrasonography evaluation, and laboratory tests will be taken using standard protocols. Participants will then be asked to wear a continuous glucose monitor (CGM) for 14-day blood glucose monitoring, which will be done by a nurse. On day 14, participants will be asked to come in for a clinical visit where they will receive their CGM report and provide blood, saliva, urine and stool samples. On day 30, participants will be asked to come in for another clinical visit where they will provide blood, saliva, urine and stool samples.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310058
- Hangzhou Third People's Hospital
-
Hangzhou, Zhejiang, China, 310030
- Westlake University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diagnosed with type 2 diabetes;
- Living in Hangzhou for at least five years;
- Have the willingness or ability to complete the intervention and sample collection
Exclusion Criteria:
- Mental and physical disability;
- Already is a vegetarian;
- Cancer and serious complications from type 2 diabetes, such as renal failure;
- Using insulin for more than 5 years;
- Unstable medical/medication status;
- Current alcohol or drug abuse;
- Taking antibiotics in the last three months
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ander
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Plant-based diet
Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period. |
After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
Andere namen:
After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
Andere namen:
After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days. Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted. |
|
Experimenteel: Conventional diabetic diet
Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period. |
After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.
Andere namen:
After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.
Andere namen:
Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted. Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Continuous glucose monitoring-derived mean blood glucose
Tijdsspanne: 2 weeks
|
Real-time glucose profiles will be recorded using continuous glucose monitoring. Average of all glucose measurements during the up to 14 days CGM wear will be calculated in mmol/L. |
2 weeks
|
|
Continuous glucose monitoring-derived time-in-range
Tijdsspanne: 2 weeks
|
Real-time glucose profiles will be recorded using continuous glucose monitoring. Percentage of glucose measurements that wear in the range of 3.9-10.0 mmol/L during the up to 14 days CGM will be calculated. |
2 weeks
|
|
Continuous glucose monitoring-derived coefficient of variation
Tijdsspanne: two weeks
|
Continuous glucose monitoring-derived time-in-range Real-time glucose profiles will be recorded using continuous glucose monitoring. Coefficient of variation was defined as standard deviation divided by mean glucose and multiplied by 100, during the up to 14 days wear. |
two weeks
|
|
Changes in gut microbiome profile
Tijdsspanne: Day 1, 15 and 31
|
Shotgun metagenomic sequencing will be performed in stool samples. |
Day 1, 15 and 31
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Changes in fasting blood glucose
Tijdsspanne: Day 1, 15 and 31
|
Fasting glucose will be examined in mmol/L. |
Day 1, 15 and 31
|
|
Changes in fasting blood C-peptide
Tijdsspanne: Day 1, 15 and 31
|
Fasting blood C-peptide will be examined in μg/L. |
Day 1, 15 and 31
|
|
Changes in fasting blood HbA1c
Tijdsspanne: Day 1, 15 and 31
|
Fasting blood HbA1c will be examined in %. |
Day 1, 15 and 31
|
|
Changes in lipid metabolism
Tijdsspanne: Day 1, 15 and 31
|
Triglyceride, cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol will be examined in mmol/L. |
Day 1, 15 and 31
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Ju-Sheng Zheng, PhD, Westlake University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Metabole ziekten
- Glucosemetabolismestoornissen
- Suikerziekte
- Voedings- en stofwisselingsziekten
- Diabetes mellitus, type 2
- Therapeutica
- Dieet, voedsel en voeding
- Fysiologische fenomenen
- Nutritionele fysiologische fenomenen
- Dieettherapie
- Voedingstherapie
- Dieet
- Dieet, plantaardig
Andere studie-ID-nummers
- 20230306ZJS002
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .